B
Cipher Pharmaceuticals Inc.
CPH.TO
TSX
B
Buy
11/24/2023Upgraded
Cipher Pharmaceuticals Inc. (CPH.TO) was upgraded to B from B- on 11/24/2023 due to a noticeable increase in the growth index, volatility index and solvency index. Earnings per share increased from $0.12 to $0.27, operating cash flow increased 102.72% from $2.95M to $5.97M, and EBIT increased 19.68% from $2.53M to $3.02M.
Cipher Pharmaceuticals Inc. (CPH.TO) was upgraded to B from B- on 11/24/2023 due to a noticeable increase in the growth index, volatility index and solvency index. Earnings per share increased from $0.12 to $0.27, operating cash flow increased 102.72% from $2.95M to $5.97M, and EBIT increased 19.68% from $2.53M to $3.02M.
B
Buy
12/16/2022Upgraded
Cipher Pharmaceuticals Inc. (CPH.TO) was upgraded to B- from C+ on 12/16/2022 due to an increase in the total return index and volatility index.
Cipher Pharmaceuticals Inc. (CPH.TO) was upgraded to B- from C+ on 12/16/2022 due to an increase in the total return index and volatility index.
C
Hold
11/16/2022Downgrade
Cipher Pharmaceuticals Inc. (CPH.TO) was downgraded to C+ from B- on 11/16/2022 due to a large decline in the growth index and valuation index. EBIT declined 34.4% from $3.37M to $2.21M, and total revenue declined 13.78% from $5.56M to $4.79M.
Cipher Pharmaceuticals Inc. (CPH.TO) was downgraded to C+ from B- on 11/16/2022 due to a large decline in the growth index and valuation index. EBIT declined 34.4% from $3.37M to $2.21M, and total revenue declined 13.78% from $5.56M to $4.79M.
B
Buy
8/18/2022Upgraded
Cipher Pharmaceuticals Inc. (CPH.TO) was upgraded to B- from C+ on 8/18/2022 due to an increase in the growth index, efficiency index and solvency index. Operating cash flow increased 50.1% from $2.1M to $3.15M, EBIT increased 16.21% from $2.9M to $3.37M, and total capital increased 3.79% from $40.87M to $42.42M.
Cipher Pharmaceuticals Inc. (CPH.TO) was upgraded to B- from C+ on 8/18/2022 due to an increase in the growth index, efficiency index and solvency index. Operating cash flow increased 50.1% from $2.1M to $3.15M, EBIT increased 16.21% from $2.9M to $3.37M, and total capital increased 3.79% from $40.87M to $42.42M.
C
Hold
6/27/2022Downgrade
Cipher Pharmaceuticals Inc. (CPH.TO) was downgraded to C+ from B- on 6/27/2022 due to a decline in the total return index.
Cipher Pharmaceuticals Inc. (CPH.TO) was downgraded to C+ from B- on 6/27/2022 due to a decline in the total return index.
B
Buy
5/16/2022Downgrade
Cipher Pharmaceuticals Inc. (CPH.TO) was downgraded to B- from B on 5/16/2022 due to a major decline in the growth index, efficiency index and solvency index. Operating cash flow declined 63.27% from $5.72M to $2.1M, EBIT declined 25.57% from $3.9M to $2.9M, and earnings per share declined from $0.1071 to $0.08.
Cipher Pharmaceuticals Inc. (CPH.TO) was downgraded to B- from B on 5/16/2022 due to a major decline in the growth index, efficiency index and solvency index. Operating cash flow declined 63.27% from $5.72M to $2.1M, EBIT declined 25.57% from $3.9M to $2.9M, and earnings per share declined from $0.1071 to $0.08.
B
Buy
4/25/2022Upgraded
Cipher Pharmaceuticals Inc. (CPH.TO) was upgraded to B from B- on 4/25/2022 due to an increase in the total return index.
Cipher Pharmaceuticals Inc. (CPH.TO) was upgraded to B from B- on 4/25/2022 due to an increase in the total return index.
B
Buy
4/18/2022Upgraded
Cipher Pharmaceuticals Inc. (CPH.TO) was upgraded to B- from C+ on 4/18/2022 due to a significant increase in the growth index, total return index and valuation index. Operating cash flow increased 1,023.18% from $509 to $5.72M, earnings per share increased from $0.03 to $0.1071, and EBIT increased 92.82% from $2.02M to $3.9M.
Cipher Pharmaceuticals Inc. (CPH.TO) was upgraded to B- from C+ on 4/18/2022 due to a significant increase in the growth index, total return index and valuation index. Operating cash flow increased 1,023.18% from $509 to $5.72M, earnings per share increased from $0.03 to $0.1071, and EBIT increased 92.82% from $2.02M to $3.9M.
C
Hold
11/30/2021Upgraded
Cipher Pharmaceuticals Inc. (CPH.TO) was upgraded to C+ from C on 11/30/2021 due to an increase in the valuation index and volatility index.
Cipher Pharmaceuticals Inc. (CPH.TO) was upgraded to C+ from C on 11/30/2021 due to an increase in the valuation index and volatility index.
C
Hold
11/15/2021Downgrade
Cipher Pharmaceuticals Inc. (CPH.TO) was downgraded to C from C+ on 11/15/2021 due to a large decline in the valuation index, growth index and efficiency index. Operating cash flow declined 84.39% from $3.26M to $509, net income declined 71.73% from $2.82M to $796, and earnings per share declined from $0.1 to $0.03.
Cipher Pharmaceuticals Inc. (CPH.TO) was downgraded to C from C+ on 11/15/2021 due to a large decline in the valuation index, growth index and efficiency index. Operating cash flow declined 84.39% from $3.26M to $509, net income declined 71.73% from $2.82M to $796, and earnings per share declined from $0.1 to $0.03.
C
Hold
8/13/2021Upgraded
Cipher Pharmaceuticals Inc. (CPH.TO) was upgraded to C+ from C- on 8/13/2021 due to a significant increase in the growth index, valuation index and total return index. Earnings per share increased from $0.0498 to $0.1, EBIT increased 14.85% from $3.33M to $3.82M, and total revenue increased 12.52% from $5.45M to $6.13M.
Cipher Pharmaceuticals Inc. (CPH.TO) was upgraded to C+ from C- on 8/13/2021 due to a significant increase in the growth index, valuation index and total return index. Earnings per share increased from $0.0498 to $0.1, EBIT increased 14.85% from $3.33M to $3.82M, and total revenue increased 12.52% from $5.45M to $6.13M.
C
Hold
6/9/2021Upgraded
Cipher Pharmaceuticals Inc. (CPH.TO) was upgraded to C- from D+ on 6/9/2021 due to an increase in the volatility index and total return index.
Cipher Pharmaceuticals Inc. (CPH.TO) was upgraded to C- from D+ on 6/9/2021 due to an increase in the volatility index and total return index.
D
Sell
5/14/2021Downgrade
Cipher Pharmaceuticals Inc. (CPH.TO) was downgraded to D+ from C on 5/14/2021 due to a significant decline in the growth index and valuation index. Operating cash flow declined 30.33% from $6.21M to $4.33M, total revenue declined 11.4% from $6.15M to $5.45M, and EBIT declined 3.26% from $3.44M to $3.33M.
Cipher Pharmaceuticals Inc. (CPH.TO) was downgraded to D+ from C on 5/14/2021 due to a significant decline in the growth index and valuation index. Operating cash flow declined 30.33% from $6.21M to $4.33M, total revenue declined 11.4% from $6.15M to $5.45M, and EBIT declined 3.26% from $3.44M to $3.33M.
C
Hold
4/28/2021Upgraded
Cipher Pharmaceuticals Inc. (CPH.TO) was upgraded to C from C- on 4/28/2021 due to an increase in the total return index.
Cipher Pharmaceuticals Inc. (CPH.TO) was upgraded to C from C- on 4/28/2021 due to an increase in the total return index.
C
Hold
3/30/2021Upgraded
Cipher Pharmaceuticals Inc. (CPH.TO) was upgraded to C- from D+ on 3/30/2021 due to an increase in the solvency index, total return index and growth index. Operating cash flow increased 438.53% from -$1.84M to $6.21M, debt to equity declined from 0.05 to 0, and EBIT increased 38.29% from $2.49M to $3.44M.
Cipher Pharmaceuticals Inc. (CPH.TO) was upgraded to C- from D+ on 3/30/2021 due to an increase in the solvency index, total return index and growth index. Operating cash flow increased 438.53% from -$1.84M to $6.21M, debt to equity declined from 0.05 to 0, and EBIT increased 38.29% from $2.49M to $3.44M.
D
Sell
11/9/2020Downgrade
Cipher Pharmaceuticals Inc. (CPH.TO) was downgraded to D+ from C- on 11/9/2020 due to a decline in the growth index, efficiency index and solvency index. Net income declined 84.44% from $2.64M to $411, earnings per share declined from $0.0961 to $0.0152, and operating cash flow declined 64.3% from $5.39M to $1.92M.
Cipher Pharmaceuticals Inc. (CPH.TO) was downgraded to D+ from C- on 11/9/2020 due to a decline in the growth index, efficiency index and solvency index. Net income declined 84.44% from $2.64M to $411, earnings per share declined from $0.0961 to $0.0152, and operating cash flow declined 64.3% from $5.39M to $1.92M.
C
Hold
8/5/2020Upgraded
Cipher Pharmaceuticals Inc. (CPH.TO) was upgraded to C- from D+ on 8/5/2020 due to an increase in the total return index, volatility index and solvency index.
Cipher Pharmaceuticals Inc. (CPH.TO) was upgraded to C- from D+ on 8/5/2020 due to an increase in the total return index, volatility index and solvency index.
D
Sell
5/11/2020Upgraded
Cipher Pharmaceuticals Inc. (CPH.TO) was upgraded to D+ from D on 5/11/2020 due to an increase in the efficiency index, volatility index and solvency index. Debt to equity declined from 0.28 to 0.19, the quick ratio increased from 0.92 to 1.2, and total capital increased 1.39% from $37.58M to $38.1M.
Cipher Pharmaceuticals Inc. (CPH.TO) was upgraded to D+ from D on 5/11/2020 due to an increase in the efficiency index, volatility index and solvency index. Debt to equity declined from 0.28 to 0.19, the quick ratio increased from 0.92 to 1.2, and total capital increased 1.39% from $37.58M to $38.1M.
D
Sell
3/27/2020Upgraded
Cipher Pharmaceuticals Inc. (CPH.TO) was upgraded to D from D- on 3/27/2020 due to a significant increase in the valuation index, growth index and efficiency index. Earnings per share increased from -$0.0771 to $0.1165, net income increased 249.66% from -$2.08M to $3.11M, and operating cash flow increased 16.13% from $1.69M to $1.97M.
Cipher Pharmaceuticals Inc. (CPH.TO) was upgraded to D from D- on 3/27/2020 due to a significant increase in the valuation index, growth index and efficiency index. Earnings per share increased from -$0.0771 to $0.1165, net income increased 249.66% from -$2.08M to $3.11M, and operating cash flow increased 16.13% from $1.69M to $1.97M.
D
Sell
3/6/2020Downgrade
Cipher Pharmaceuticals Inc. (CPH.TO) was downgraded to D- from D on 3/6/2020 due to a significant decline in the valuation index, growth index and total return index. Earnings per share declined from $0.0513 to -$0.0771, and operating cash flow declined 48.76% from $3.3M to $1.69M.
Cipher Pharmaceuticals Inc. (CPH.TO) was downgraded to D- from D on 3/6/2020 due to a significant decline in the valuation index, growth index and total return index. Earnings per share declined from $0.0513 to -$0.0771, and operating cash flow declined 48.76% from $3.3M to $1.69M.
D
Sell
9/30/2019Upgraded
Cipher Pharmaceuticals Inc. (CPH.TO) was upgraded to D from D- on 9/30/2019 due to an increase in the total return index, volatility index and solvency index.
Cipher Pharmaceuticals Inc. (CPH.TO) was upgraded to D from D- on 9/30/2019 due to an increase in the total return index, volatility index and solvency index.
D
Sell
8/13/2019Downgrade
Cipher Pharmaceuticals Inc. (CPH.TO) was downgraded to D- from D on 8/13/2019 due to a noticeable decline in the valuation index and efficiency index. Total capital declined 0.96% from $44.4M to $43.97M.
Cipher Pharmaceuticals Inc. (CPH.TO) was downgraded to D- from D on 8/13/2019 due to a noticeable decline in the valuation index and efficiency index. Total capital declined 0.96% from $44.4M to $43.97M.
D
Sell
8/5/2019Upgraded
Cipher Pharmaceuticals Inc. (CPH.TO) was upgraded to D from D- on 8/5/2019 due to an increase in the valuation index and volatility index.
Cipher Pharmaceuticals Inc. (CPH.TO) was upgraded to D from D- on 8/5/2019 due to an increase in the valuation index and volatility index.
D
Sell
6/17/2019Downgrade
Cipher Pharmaceuticals Inc. (CPH.TO) was downgraded to D- from D on 6/17/2019 due to a decline in the volatility index and total return index.
Cipher Pharmaceuticals Inc. (CPH.TO) was downgraded to D- from D on 6/17/2019 due to a decline in the volatility index and total return index.
D
Sell
5/15/2019Upgraded
Cipher Pharmaceuticals Inc. (CPH.TO) was upgraded to D from D- on 5/15/2019 due to a significant increase in the valuation index and efficiency index. Net income increased 175.21% from -$1.09M to $816, and total capital increased 4.37% from $42.54M to $44.4M.
Cipher Pharmaceuticals Inc. (CPH.TO) was upgraded to D from D- on 5/15/2019 due to a significant increase in the valuation index and efficiency index. Net income increased 175.21% from -$1.09M to $816, and total capital increased 4.37% from $42.54M to $44.4M.
D
Sell
3/29/2019Downgrade
Cipher Pharmaceuticals Inc. (CPH.TO) was downgraded to D- from D on 3/29/2019 due to a significant decline in the valuation index, efficiency index and total return index. Net income declined 254.78% from $701 to -$1.09M, and total capital declined 5.64% from $45.08M to $42.54M.
Cipher Pharmaceuticals Inc. (CPH.TO) was downgraded to D- from D on 3/29/2019 due to a significant decline in the valuation index, efficiency index and total return index. Net income declined 254.78% from $701 to -$1.09M, and total capital declined 5.64% from $45.08M to $42.54M.
D
Sell
11/14/2018Downgrade
Cipher Pharmaceuticals Inc. (CPH.TO) was downgraded to D from D+ on 11/14/2018 due to a significant decline in the growth index and solvency index. Operating cash flow declined 532.26% from $31 to -$134, EBIT declined 62.48% from $2.85M to $1.07M, and earnings per share declined from $0.0779 to $0.03.
Cipher Pharmaceuticals Inc. (CPH.TO) was downgraded to D from D+ on 11/14/2018 due to a significant decline in the growth index and solvency index. Operating cash flow declined 532.26% from $31 to -$134, EBIT declined 62.48% from $2.85M to $1.07M, and earnings per share declined from $0.0779 to $0.03.
D
Sell
8/16/2018Upgraded
Cipher Pharmaceuticals Inc. (CPH.TO) was upgraded to D+ from D on 8/16/2018 due to a significant increase in the valuation index, growth index and efficiency index. EBIT increased 356.57% from $624 to $2.85M, net income increased 277.19% from -$1.2M to $2.13M, and earnings per share increased from -$0.0492 to $0.0779.
Cipher Pharmaceuticals Inc. (CPH.TO) was upgraded to D+ from D on 8/16/2018 due to a significant increase in the valuation index, growth index and efficiency index. EBIT increased 356.57% from $624 to $2.85M, net income increased 277.19% from -$1.2M to $2.13M, and earnings per share increased from -$0.0492 to $0.0779.
D
Sell
11/3/2017Upgraded
Cipher Pharmaceuticals Inc. (CPH.TO) was upgraded to D from D- on 11/3/2017 due to a noticeable increase in the solvency index, growth index and efficiency index. Operating cash flow increased 741.59% from $1.36M to $11.45M, net income increased 134.3% from $1.17M to $2.74M, and earnings per share increased from $0.0441 to $0.1.
Cipher Pharmaceuticals Inc. (CPH.TO) was upgraded to D from D- on 11/3/2017 due to a noticeable increase in the solvency index, growth index and efficiency index. Operating cash flow increased 741.59% from $1.36M to $11.45M, net income increased 134.3% from $1.17M to $2.74M, and earnings per share increased from $0.0441 to $0.1.
D
Sell
8/11/2017Downgrade
Cipher Pharmaceuticals Inc. (CPH.TO) was downgraded to D- from D on 8/11/2017 due to a decline in the growth index and efficiency index. Total capital declined 34.74% from $54.71M to $35.7M.
Cipher Pharmaceuticals Inc. (CPH.TO) was downgraded to D- from D on 8/11/2017 due to a decline in the growth index and efficiency index. Total capital declined 34.74% from $54.71M to $35.7M.
D
Sell
6/23/2017Upgraded
Cipher Pharmaceuticals Inc. (CPH.TO) was upgraded to D from D- on 6/23/2017 due to a noticeable increase in the growth index, volatility index and total return index. EBIT increased 952% from -$550 to $4.69M, and earnings per share increased from -$0.4294 to -$0.1257.
Cipher Pharmaceuticals Inc. (CPH.TO) was upgraded to D from D- on 6/23/2017 due to a noticeable increase in the growth index, volatility index and total return index. EBIT increased 952% from -$550 to $4.69M, and earnings per share increased from -$0.4294 to -$0.1257.
D
Sell
3/3/2017Downgrade
Cipher Pharmaceuticals Inc. (CPH.TO) was downgraded to D- from D on 3/3/2017 due to a significant decline in the efficiency index, solvency index and valuation index. Debt to equity increased from 1.22 to 2.02, total capital declined 16.8% from $65.37M to $54.39M, and the quick ratio declined from 2.41 to 2.35.
Cipher Pharmaceuticals Inc. (CPH.TO) was downgraded to D- from D on 3/3/2017 due to a significant decline in the efficiency index, solvency index and valuation index. Debt to equity increased from 1.22 to 2.02, total capital declined 16.8% from $65.37M to $54.39M, and the quick ratio declined from 2.41 to 2.35.
D
Sell
9/12/2016Downgrade
Cipher Pharmaceuticals Inc. (CPH.TO) was downgraded to D from D+ on 9/12/2016 due to a large decline in the total return index, volatility index and efficiency index. Net income declined 25.13% from -$2.69M to -$3.37M, and total capital declined 2.49% from $87.44M to $85.26M.
Cipher Pharmaceuticals Inc. (CPH.TO) was downgraded to D from D+ on 9/12/2016 due to a large decline in the total return index, volatility index and efficiency index. Net income declined 25.13% from -$2.69M to -$3.37M, and total capital declined 2.49% from $87.44M to $85.26M.
D
Sell
5/6/2016Downgrade
Cipher Pharmaceuticals Inc. (CPH.TO) was downgraded to D+ from C- on 5/6/2016 due to a noticeable decline in the growth index, efficiency index and valuation index. Net income declined 232.06% from $2.04M to -$2.69M, earnings per share declined from $0.0783 to -$0.1, and total revenue declined 6.37% from $9.71M to $9.1M.
Cipher Pharmaceuticals Inc. (CPH.TO) was downgraded to D+ from C- on 5/6/2016 due to a noticeable decline in the growth index, efficiency index and valuation index. Net income declined 232.06% from $2.04M to -$2.69M, earnings per share declined from $0.0783 to -$0.1, and total revenue declined 6.37% from $9.71M to $9.1M.
C
Hold
3/11/2016Downgrade
Cipher Pharmaceuticals Inc. (CPH.TO) was downgraded to C- from C on 3/11/2016 due to a significant decline in the volatility index, efficiency index and growth index. Operating cash flow declined 16.72% from $1.56M to $1.3M.
Cipher Pharmaceuticals Inc. (CPH.TO) was downgraded to C- from C on 3/11/2016 due to a significant decline in the volatility index, efficiency index and growth index. Operating cash flow declined 16.72% from $1.56M to $1.3M.
C
Hold
2/24/2016Downgrade
Cipher Pharmaceuticals Inc. (CPH.TO) was downgraded to C from C+ on 2/24/2016 due to a decline in the total return index, volatility index and valuation index.
Cipher Pharmaceuticals Inc. (CPH.TO) was downgraded to C from C+ on 2/24/2016 due to a decline in the total return index, volatility index and valuation index.
C
Hold
1/21/2016Upgraded
Cipher Pharmaceuticals Inc. (CPH.TO) was upgraded to C+ from C on 1/21/2016 due to an increase in the valuation index and volatility index.
Cipher Pharmaceuticals Inc. (CPH.TO) was upgraded to C+ from C on 1/21/2016 due to an increase in the valuation index and volatility index.
C
Hold
12/23/2015Downgrade
Cipher Pharmaceuticals Inc. (CPH.TO) was downgraded to C from C+ on 12/23/2015 due to a decline in the valuation index.
Cipher Pharmaceuticals Inc. (CPH.TO) was downgraded to C from C+ on 12/23/2015 due to a decline in the valuation index.
C
Hold
11/30/2015Upgraded
Cipher Pharmaceuticals Inc. (CPH.TO) was upgraded to C+ from C on 11/30/2015 due to an increase in the valuation index.
Cipher Pharmaceuticals Inc. (CPH.TO) was upgraded to C+ from C on 11/30/2015 due to an increase in the valuation index.
C
Hold
11/13/2015Downgrade
Cipher Pharmaceuticals Inc. (CPH.TO) was downgraded to C from C+ on 11/13/2015 due to a decline in the valuation index and volatility index.
Cipher Pharmaceuticals Inc. (CPH.TO) was downgraded to C from C+ on 11/13/2015 due to a decline in the valuation index and volatility index.
C
Hold
11/5/2015Downgrade
Cipher Pharmaceuticals Inc. (CPH.TO) was downgraded to C+ from B+ on 11/5/2015 due to a significant decline in the valuation index, total return index and efficiency index. Total capital declined 0.92% from $86.78M to $85.98M.
Cipher Pharmaceuticals Inc. (CPH.TO) was downgraded to C+ from B+ on 11/5/2015 due to a significant decline in the valuation index, total return index and efficiency index. Total capital declined 0.92% from $86.78M to $85.98M.
B
Buy
9/9/2015Upgraded
Cipher Pharmaceuticals Inc. (CPH.TO) was upgraded to B+ from B on 9/9/2015 due to a noticeable increase in the valuation index, growth index and solvency index.
Cipher Pharmaceuticals Inc. (CPH.TO) was upgraded to B+ from B on 9/9/2015 due to a noticeable increase in the valuation index, growth index and solvency index.
B
Buy
8/14/2015Downgrade
Cipher Pharmaceuticals Inc. (CPH.TO) was downgraded to B from B+ on 8/14/2015 due to a major decline in the growth index, solvency index and valuation index. Earnings per share declined from $0.0967 to -$0.02, EBIT declined 91.86% from $3.44M to $280, and the quick ratio declined from 4.84 to 0.88.
Cipher Pharmaceuticals Inc. (CPH.TO) was downgraded to B from B+ on 8/14/2015 due to a major decline in the growth index, solvency index and valuation index. Earnings per share declined from $0.0967 to -$0.02, EBIT declined 91.86% from $3.44M to $280, and the quick ratio declined from 4.84 to 0.88.
B
Buy
7/1/2015Downgrade
Cipher Pharmaceuticals Inc. (CPH.TO) was downgraded to B+ from A- on 7/1/2015 due to a major decline in the volatility index.
Cipher Pharmaceuticals Inc. (CPH.TO) was downgraded to B+ from A- on 7/1/2015 due to a major decline in the volatility index.
A
Buy
6/11/2015Upgraded
Cipher Pharmaceuticals Inc. (CPH.TO) was upgraded to A- from B+ on 6/11/2015 due to an increase in the valuation index and volatility index.
Cipher Pharmaceuticals Inc. (CPH.TO) was upgraded to A- from B+ on 6/11/2015 due to an increase in the valuation index and volatility index.
B
Buy
5/19/2015Downgrade
Cipher Pharmaceuticals Inc. (CPH.TO) was downgraded to B+ from A- on 5/19/2015 due to a decline in the valuation index and solvency index. The quick ratio declined from 5.24 to 4.84.
Cipher Pharmaceuticals Inc. (CPH.TO) was downgraded to B+ from A- on 5/19/2015 due to a decline in the valuation index and solvency index. The quick ratio declined from 5.24 to 4.84.
A
Buy
5/11/2015Upgraded
Cipher Pharmaceuticals Inc. (CPH.TO) was upgraded to A- from B+ on 5/11/2015 due to an increase in the valuation index.
Cipher Pharmaceuticals Inc. (CPH.TO) was upgraded to A- from B+ on 5/11/2015 due to an increase in the valuation index.
B
Buy
4/17/2015Downgrade
Cipher Pharmaceuticals Inc. (CPH.TO) was downgraded to B+ from A- on 4/17/2015 due to a large decline in the total return index.
Cipher Pharmaceuticals Inc. (CPH.TO) was downgraded to B+ from A- on 4/17/2015 due to a large decline in the total return index.
A
Buy
3/23/2015Upgraded
Cipher Pharmaceuticals Inc. (CPH.TO) was upgraded to A- from B+ on 3/23/2015 due to an increase in the valuation index and volatility index.
Cipher Pharmaceuticals Inc. (CPH.TO) was upgraded to A- from B+ on 3/23/2015 due to an increase in the valuation index and volatility index.
B
Buy
3/6/2015Downgrade
Cipher Pharmaceuticals Inc. (CPH.TO) was downgraded to B+ from A on 3/6/2015 due to a major decline in the valuation index, growth index and total return index. Earnings per share declined from $0.3031 to $0.1242, and operating cash flow declined 22.74% from $6.55M to $5.06M.
Cipher Pharmaceuticals Inc. (CPH.TO) was downgraded to B+ from A on 3/6/2015 due to a major decline in the valuation index, growth index and total return index. Earnings per share declined from $0.3031 to $0.1242, and operating cash flow declined 22.74% from $6.55M to $5.06M.
A
Buy
12/9/2014Downgrade
Cipher Pharmaceuticals Inc. (CPH.TO) was downgraded to A from A+ on 12/9/2014 due to a decline in the valuation index.
Cipher Pharmaceuticals Inc. (CPH.TO) was downgraded to A from A+ on 12/9/2014 due to a decline in the valuation index.
A
Buy
11/19/2014Upgraded
Cipher Pharmaceuticals Inc. (DND.TO) was upgraded to A+ from A on 11/19/2014 due to a major increase in the total return index, efficiency index and growth index. Earnings per share increased from $0.1559 to $0.3031, net income increased 92.44% from $4.13M to $7.95M, and operating cash flow increased 60.67% from $4.08M to $6.55M.
Cipher Pharmaceuticals Inc. (DND.TO) was upgraded to A+ from A on 11/19/2014 due to a major increase in the total return index, efficiency index and growth index. Earnings per share increased from $0.1559 to $0.3031, net income increased 92.44% from $4.13M to $7.95M, and operating cash flow increased 60.67% from $4.08M to $6.55M.
A
Buy
8/1/2014Upgraded
Cipher Pharmaceuticals Inc. (DND.TO) was upgraded to A from A- on 8/1/2014 due to a significant increase in the growth index, total return index and volatility index. EBIT increased 19.47% from $4.46M to $5.33M, earnings per share increased from $0.136 to $0.1559, and total revenue increased 12.15% from $7.14M to $8.01M.
Cipher Pharmaceuticals Inc. (DND.TO) was upgraded to A from A- on 8/1/2014 due to a significant increase in the growth index, total return index and volatility index. EBIT increased 19.47% from $4.46M to $5.33M, earnings per share increased from $0.136 to $0.1559, and total revenue increased 12.15% from $7.14M to $8.01M.
A
Buy
3/7/2014Upgraded
Cipher Pharmaceuticals Inc. (DND.TO) was upgraded to A- from B+ on 3/7/2014 due to a substantial increase in the valuation index, growth index and volatility index. Earnings per share increased from $0.1252 to $0.6191, EBIT increased 212.45% from $3.18M to $9.93M, and total revenue increased 120.19% from $5.43M to $11.95M.
Cipher Pharmaceuticals Inc. (DND.TO) was upgraded to A- from B+ on 3/7/2014 due to a substantial increase in the valuation index, growth index and volatility index. Earnings per share increased from $0.1252 to $0.6191, EBIT increased 212.45% from $3.18M to $9.93M, and total revenue increased 120.19% from $5.43M to $11.95M.
